Patents Assigned to Medical University
-
Publication number: 20240309060Abstract: Described herein are polypeptides comprising at least one nucleophosmin-binding domain, including engineered polypeptides, and methods of using such polypeptides to treat or prevent acute kidney injury and/or kidney ischemia.Type: ApplicationFiled: March 15, 2024Publication date: September 19, 2024Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATIONInventors: Steven C. Borkan, Aaron B. Beeler, Zhiyong Wang, Jac Lorenzo, Karen N. Allen
-
Patent number: 12090251Abstract: A cell sheet for transplantation into a living body, containing MSCs having an average cell density of 3.0×104 cells/cm2 or less on the surface of the sheet is provided. A method for producing a cell sheet for transplantation into a living body, including: a step of seeding MSCs on a cell culture carrier having a three-dimensional structure formed of fibers at a cell number of 3.0×105 cells/cm2 or less; and a step of culturing the MSCs and thereby preparing a cell sheet containing the MSCs having an average cell density of 3.0×104 cells/cm2 or less is also provided.Type: GrantFiled: April 25, 2019Date of Patent: September 17, 2024Assignee: Sapporo Medical UniversityInventors: Takako Chikenji, Mineko Fujimiya, Yuki Saito, Masako Nakano, Naoto Konari, Miho Otani
-
Patent number: 12090156Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.Type: GrantFiled: February 15, 2023Date of Patent: September 17, 2024Assignee: INSTITUTE OF OPHTHALMOLOGY AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG INSTITUTE OF OPHTHALMOInventors: Weiyun Shi, Qingjun Zhou, Hongwei Wang, Bining Zhang
-
Patent number: 12082574Abstract: The present invention provides a composition that can preserve biomaterials. The biomaterial preservation composition of the present invention includes a micro bubble.Type: GrantFiled: May 31, 2019Date of Patent: September 10, 2024Assignees: AICHI MEDICAL UNIVERSITY, SUMITOMO SEIKA CHEMICALS CO., LTD.Inventors: Naoyuki Hatayama, Munekazu Naito, Shuichi Hirai, Shigeki Sakaue
-
Patent number: 12076443Abstract: A preparation method of a nanozyme composite-based hybrid hydrogel eye drop includes synthesizing a tannin-coordinated silver/cobalt composite nanoparticle through a coordination reaction of cobalt chloride hexahydrate with ammonia water and an oxidation-reduction reaction of silver nitrate with tannin; and mixing the silver/cobalt composite nanoparticle with an acrylate-modified gelatin, conducting an ultrasonic treatment to allow complete dissolution, and irradiating a resulting mixture under ultraviolet (UV) light to obtain the nanozyme composite-based hybrid hydrogel eye drop. The preparation method of the present disclosure has simple operations and a short preparation time. The eye drop prepared by the preparation method shows a broad-spectrum bactericidal effect against a variety of bacteria and fungi, and has prominent preventive and therapeutic effects for bacterial and drug-resistant bacterial corneal infections.Type: GrantFiled: February 15, 2023Date of Patent: September 3, 2024Assignee: INSTITUTE OF OPHTHALMOLOGY AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG INSTITUTE OF OPHTHALMOLOGY, QINGDAO EYE HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY)Inventors: Qingjun Zhou, Weiyun Shi, Hongwei Wang, Fangying Song
-
Publication number: 20240287570Abstract: A method for assessing drug-resistant Stenotrophomonas maltophilia includes the following steps. A test sample is provided, wherein the test sample includes a Stenotrophomonas maltophilia. A spectrum analysis step is performed, wherein the test sample is detected by a mass spectrometry method so as to obtain a target mass spectrum data. An assessing step for drug-resistant Stenotrophomonas maltophilia is performed, wherein the target mass spectrum data is analyzed so as to assess whether the Stenotrophomonas maltophilia is susceptible or resistant to a ceftazidime antibiotic. When the Stenotrophomonas maltophilia is susceptible to the ceftazidime, the target mass spectrum data includes a first anti-ceftazidime feature mark, and a mass-to-charge ratio of the first anti-ceftazidime feature mark ranges from 5,965 to 5,975 daltons. When the Stenotrophomonas maltophilia is resistant to the ceftazidime, the target mass spectrum data is without a peak at the first anti-ceftazidime feature mark.Type: ApplicationFiled: February 24, 2023Publication date: August 29, 2024Applicant: China Medical UniversityInventors: Der-Yang Cho, Po-Ren Hsueh, Jiaxin Yu, Chia-Fong Cho
-
Publication number: 20240288524Abstract: A magnetic resonance imaging (MRI) system and method integrating multi-nuclide synchronous imaging and spectral imaging is provided. The MRI system includes a spectral imaging module, a multi-nuclide synchronous imaging module, and a spectral reconstruction and image fusion module, where the spectral imaging module is configured to acquire a spectrum of a nuclide Nuc; the multi-nuclide synchronous imaging module is configured to perform synchronous imaging of nuclides Nuc1 . . . . Nucn, where when n=1, Nucl is 1H; and when n>1, Nucn is a non-1H nuclide; and the spectral reconstruction and image fusion module is configured to receive the spectrum of the nuclide Nuc and images of the nuclides Nuc1 . . . . Nucn, and acquire spatial distribution information of compounds of the nuclide Nuc and spatial distribution information of the non-1H nuclide through fusion. The system and method can synchronously acquire MR signals of different nuclides, and reconstruct and fuse non-1H nuclide images.Type: ApplicationFiled: February 21, 2024Publication date: August 29, 2024Applicant: Harbin Medical UniversityInventors: Xilin SUN, Chunsheng YANG, Kai WANG, Yongyi WU, Lijiao WANG, Lili YANG, Lina WU
-
Patent number: 12071612Abstract: The present disclosure relates to the technical field of microorganisms, in particular to Lactobacillus gasseri HMV18 and a secreted protein and an application thereof. The Lactobacillus gasseri HMV18 is preserved in the China Center for Type Culture Collection on Jul. 11, 2019 with a preservation number of CCTCC NO: M 2019538, and a preservation address of Wuhan University, Wuhan, China. The protein extracted from the Lactobacillus gasseri HMV18 has antibacterial and anti-tumor effects, but basically has no effect on normal myocardial cells, so the Lactobacillus gasseri HMV18 can be applied to preparation of antibacterial and anti-tumor products.Type: GrantFiled: April 30, 2021Date of Patent: August 27, 2024Assignee: Hebei Medical UniversityInventors: Bin Cong, Xianxian Jia
-
Publication number: 20240280659Abstract: The present disclosure provides an imaging method using a mobile magnetic resonance apparatus, which includes: randomly sampling an object-to-be-scanned using a mobile magnetic resonance apparatus to acquire encoding of the frequency and phase of the tissue of the object-to-be-scanned, and obtain target K-space data; inputting the target K-space data and pre-generated denoising reconstruction network parameters into a pre-trained denoising reconstruction network; where the pre-trained denoising reconstruction network is generated by training based on fully sampled training data; and outputting a magnetic resonance image corresponding to the object-to-be-scanned.Type: ApplicationFiled: February 16, 2024Publication date: August 22, 2024Applicant: Beijing Chao-Yang Hospital, Capital Medical UniversityInventors: Qi YANG, Yueyan BIAN, Xiuqin JIA, Xiaoxu YANG
-
Patent number: 12067897Abstract: A training device (1) for fracture reduction, comprising: a fracture reduction platform (20) having a base (202) and a robotic arm section (201) fixed on the base (202), the robotic arm section (201) being configured in such a manner that a limb model can be mounted thereon; and a control unit (30) coupled to the fracture reduction platform (20) and configured to simulate and present, based on the motion of the robotic arm section (201), the effect of the motion of the robotic arm section (201) on the limb model. Also provided is a training method for fracture reduction.Type: GrantFiled: October 29, 2019Date of Patent: August 20, 2024Assignee: INNER MONGOLIA MEDICAL UNIVERSITYInventors: Qizhu Wu, Galatai, Yingsong Chen, Agula, Murigenjiya, Changsheng Li
-
Publication number: 20240262871Abstract: A fusion protein for detecting neurosyphilis and a kit thereof are provided in this disclosure. It is unexpectedly found in this disclosure that detecting the Nichols Houston strain TP0136 antibody level for diagnosis of neurosyphilis makes up a blank of diagnosis and detection methods of the neurosyphilis. Using molecular biology gene cloning and expression technologies, a syphilis Nichols Houston strain TP0136 recombinant protein is obtained, a luciferase immunoprecipitation method for detecting a Nichols Houston strain TP0136 antibody is established, and a kit is assembled. Such a kit has such unexpected technical effects of high sensitivity and high prediction accuracy, and has advantages of large detection throughput, simple operation and easy popularization.Type: ApplicationFiled: March 17, 2023Publication date: August 8, 2024Applicant: Dermatology Hospital, Southern Medical UniversityInventors: Wujian KE, Xiaohui Zhang, Liuyuan Wang, Yujiao Wu, Xinying Leng, Sheng Ke
-
Publication number: 20240261281Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.Type: ApplicationFiled: February 15, 2023Publication date: August 8, 2024Applicant: Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute ofInventors: Weiyun SHI, Qingjun ZHOU, Hongwei WANG, Bining ZHANG
-
Publication number: 20240261231Abstract: A preparation method of a nanozyme composite-based hybrid hydrogel eye drop includes synthesizing a tannin-coordinated silver/cobalt composite nanoparticle through a coordination reaction of cobalt chloride hexahydrate with ammonia water and an oxidation-reduction reaction of silver nitrate with tannin; and mixing the silver/cobalt composite nanoparticle with an acrylate-modified gelatin, conducting an ultrasonic treatment to allow complete dissolution, and irradiating a resulting mixture under ultraviolet (UV) light to obtain the nanozyme composite-based hybrid hydrogel eye drop. The preparation method of the present disclosure has simple operations and a short preparation time. The eye drop prepared by the preparation method shows a broad-spectrum bactericidal effect against a variety of bacteria and fungi, and has prominent preventive and therapeutic effects for bacterial and drug-resistant bacterial corneal infections.Type: ApplicationFiled: February 15, 2023Publication date: August 8, 2024Applicant: Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute ofInventors: Qingjun ZHOU, Weiyun SHI, Hongwei WANG, Fangying SONG
-
Publication number: 20240264171Abstract: Biomarker of HIV or SIV infected cells and its application are provided. The marker is PLK (polo-like kinase). By inhibiting the activity of a PLK protein or clearing the same, the purpose of releasing viruses without activating a repository is achieved, such that the viruses can be detected in a physiological state and can also be recognized and cleared by an immune system or a drug in vivo. Enhancing the activity of the PLK protein directly inhibits the release of viruses in an HIV and/or SIV-infected cell. The present invention provides a new target for diagnosis and antiviral therapy of HIV and/or SIV infection, provides medication basis and guarantee for the early rapid detection and extremely early treatment of virus infection, and has important clinical value.Type: ApplicationFiled: September 30, 2021Publication date: August 8, 2024Applicant: THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITYInventors: Guoxin LIANG, Hong SHANG
-
Publication number: 20240252542Abstract: An exosome, a preparation method of an exosome, uses of the exosome, and a pharmaceutical composition including the exosome for treating an ischemia condition of a tissue are provided. The exosome is derived from a genetically engineered mesenchymal stem cell, and the genetically engineered mesenchymal stem cell includes an exogenous PD-L1 gene and an exogenous HGF gene.Type: ApplicationFiled: January 29, 2024Publication date: August 1, 2024Applicant: China Medical UniversityInventors: Long-Bin Jeng, Mien-Chie Hung, Woei-Cherng Shyu, Syuan-Ling Lin, Chien-Lin Chen
-
Publication number: 20240247032Abstract: A method for preparing amphiphiles with dendrimeric skeletons by a solid phase linker approach.Type: ApplicationFiled: August 23, 2021Publication date: July 25, 2024Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Chai-Lin Kao, Hui-Ting Chen, Vijayasimha Molakaseema, Anand Selvaraj
-
Publication number: 20240245338Abstract: A computer-implemented method of determining one or more target sites usable for treatment of ventricular tachycardia is proposed including receiving three-dimensional model data indicative of a cardiac model modelling an anatomy of a heart of a subject with fibrosis, wherein the cardiac model includes at least one myocardial segment associated with and/or modelled as electrically conducting myocardial tissue and at least one fibrotic segment associated with and/or modelled as insulating fibrotic tissue, simulating the evolution of a cardiac activation wave across the at least one myocardial segment and the at least one fibrotic segment, and determining at least one split location, at which an isosurface of the simulated wave is split into two or more sections, the at least one split location being indicative of a location for the simulated wave hitting a boundary between the at least one fibrotic segment and the at least one myocardial segment.Type: ApplicationFiled: August 11, 2022Publication date: July 25, 2024Applicants: MEDICAL UNIVERSITY OF GRAZ, KING'S COLLEGE LONDON, NUMERICOR GmbHInventors: Gernot PLANK, Martin BISHOP, Aurel NEIC, Fernando Otaviano CAMPOS
-
Publication number: 20240241140Abstract: The present invention includes a method for examining the progression of chronic kidney disease in a subject. The method includes measuring the creatinine concentration in the blood and urine of the subject and the phosphorus concentration in the urine. Next, an estimate for the phosphorous concentration in the primary urine on the basis of Formula (II): ePTFp = Up Ucr × Scr × 3.33 ( II ) is calculated, followed by comparing the estimate for the phosphorus concentration in the primary urine with the phosphorus concentration in the primary urine of a normal subject. Another aspect of the invention relates to a method for suppressing the progression of chronic kidney disease in a non-human mammal subject.Type: ApplicationFiled: April 26, 2022Publication date: July 18, 2024Applicant: JICHI MEDICAL UNIVERSITYInventor: Makoto KUROO
-
Publication number: 20240238345Abstract: The object of the present invention is to provide a preventive and/or therapeutic agent for pressure ulcers comprising a conditioned medium of immortalized mesenchymal stem cells to which specific genes are introduced as an active ingredient. The present invention provides the preventive and/or therapeutic agent for pressure ulcers comprising the conditioned medium of immortalized mesenchymal stem cells, to which hTERT or pTERT gene, bmi-1 gene, HPV-E6 gene, and HPV-E7 gene are introduced, as an active ingredient. Here, the mesenchymal stem cells are preferably obtained from either human or swine.Type: ApplicationFiled: May 19, 2022Publication date: July 18, 2024Applicants: TOKYO MEDICAL UNIVERSITY, CYSAY INC.Inventors: Takayuki Yoshimoto, Yasuhiro Katahira, Yasuhiro Yamashita
-
Publication number: 20240233572Abstract: A virtual reality acupuncture system contains a virtual reality device comprising: a head-mounted display for viewing a virtual scene model and a mannequin, and a joystick for tracking hand movements for needle insertion determination; an computing host that transmits data with a head-mounted display and constructs an acupoint database, and an acupuncture virtual reality application which is executed to build a virtual reality model, in which the acupuncture virtual reality application constructs a situational scene model for simulating the actual condition of the consultation room; and a virtual 3D spherical acupoint model of the human body, which has a sphere area located at a certain depth below the skin surface, and has a skin distance model, so that the needle can sense the distance depth after touching the skin, which can be used to determine whether the needle position is not outside the sphere area.Type: ApplicationFiled: January 5, 2024Publication date: July 11, 2024Applicant: China Medical UniversityInventors: Sheng-Teng Huang, Wei-Te Huang, Chin-Wei Chang, Mien-Chie Hung, Jaung-Geng Lin, Mao-Feng Sun, Kun-San Chao, Shi-Chen Ou, Yu-Chuan Lin, Hao-Hsiu Hung, Ting-Yu Huang, Po-En Chen